All In Biotech

Drug Trial Radar · NCT04195633

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

Hematopoietic Stem Cell Transplantation From Haploidentical Donors in Patients With Hematological Malignancies Using a Treosulfan-Based Preparative Regimen

Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Jan 25, 2021

Primary completion

Apr 15, 2027

Study completion Mar 12, 2029

Sponsor

Lead sponsor
Fred Hutchinson Cancer CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
medac GmbH
First posted
Dec 12, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 months
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This phase II trial studies how well a donor stem cell transplant, treosulfan, fludarabine, and total-body irradiation work in treating patients with blood cancers (hematological malignancies). Giving chemotherapy and total-body irradiation before a donor stem cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient, they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. The donated stem cells may also replace the patient's immune cells and help destroy any remaining cancer cells.

Conditions

  • Acute Leukemia
  • Acute Lymphoblastic Leukemia
  • Acute Myeloid Leukemia
  • Adult Diffuse Large Cell Lymphoma
  • Anaplastic Large Cell Lymphoma
  • Burkitt Lymphoma
  • Chronic Myeloid Leukemia, BCR-ABL1 Positive
  • Chronic Myelomonocytic Leukemia
  • Hodgkin Lymphoma
  • Lymphoblastic Lymphoma
  • Lymphoplasmacytic Lymphoma
  • Mantle Cell Lymphoma
  • Mixed Phenotype Acute Leukemia
  • Myelodysplastic Syndrome
  • Prolymphocytic Leukemia
  • Refractory Chronic Lymphocytic Leukemia
  • Refractory Follicular Lymphoma
  • Refractory Marginal Zone Lymphoma
  • Refractory Small Lymphocytic Lymphoma

Interventions

  • Allogeneic Hematopoietic Stem Cell TransplantationProcedure

    Undergo allogeneic hematopoietic stem cell transplantation

  • CyclophosphamideDrug

    Given IV

  • CyclosporineDrug

    Given IV or PO

  • FilgrastimBiological

    Given IV

  • FludarabineDrug

    Given IV

  • Mycophenolate MofetilDrug

    Given IV or PO

  • Mycophenolate SodiumDrug

    Given PO

  • Total-Body IrradiationRadiation

    Undergo total-body irradiation

  • TreosulfanDrug

    Given IV

  • Bone Marrow AspirationProcedure

    Undergo bone marrow aspiration

  • Bone Marrow BiopsyProcedure

    Undergo bone marrow biopsy

  • Echocardiography TestProcedure

    Undergo echocardiography

  • Biospecimen CollectionProcedure

    Undergo blood sample collection

  • Computed TomographyProcedure

    Undergo CT or PET/CT

  • Positron Emission TomographyProcedure

    Undergo PET/CT

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Graft failure/rejectionTime frame: Up to 2 years post-transplant

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fred Hutch/University of Washington Cancer Consortium

    Seattle, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.